Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

• Egile Nagusiak: Sabrina Rossi (Egilea), Alessandra Cassano (Egilea), Antonia Strippoli (Egilea), Giovanni Schinzari (Egilea), Ettore D'Argento (Egilea), Michele Basso (Egilea), Carlo Barone (Egilea)
• Formatua: Liburua
• Argitaratua: BioExcel Publishing Ltd, 2017-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background: Eribulin mesylate is currently approved in the United States and Europe for the treatment of metastatic breast cancer (MBC). Scope: The objective of this retrospective study is to find specific predictive criteria related to patient or tumor characteristics in order to select pa...